Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CEO Amirali Talasaz sold 116,972 shares of Guardant Health stock in a transaction on Friday, June 26th. The shares were sold at an average price of $150.79, for a total transaction of $17,638,207.88. Following the transaction, the chief executive officer owned 1,881,336 shares in the company, valued at approximately $283,686,655.44. This trade represents a 5.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Amirali Talasaz also recently made the following trade(s):
- On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The shares were sold at an average price of $151.54, for a total value of $21,674,463.12.
- On Wednesday, May 20th, Amirali Talasaz sold 210,000 shares of Guardant Health stock. The stock was sold at an average price of $109.89, for a total transaction of $23,076,900.00.
- On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The stock was sold at an average price of $100.32, for a total transaction of $5,016,000.00.
Guardant Health Trading Down 2.4%
NASDAQ:GH opened at $150.03 on Wednesday. The business's 50-day moving average is $115.18 and its 200 day moving average is $104.71. Guardant Health, Inc. has a 12 month low of $40.35 and a 12 month high of $153.95. The company has a market capitalization of $19.89 billion, a P/E ratio of -44.26 and a beta of 1.61.
Institutional Investors Weigh In On Guardant Health
A number of institutional investors have recently added to or reduced their stakes in GH. World Investment Advisors bought a new stake in shares of Guardant Health in the 4th quarter valued at about $1,664,000. Segall Bryant & Hamill LLC lifted its position in Guardant Health by 57.8% during the third quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company's stock valued at $19,066,000 after acquiring an additional 111,822 shares during the last quarter. TD Asset Management Inc lifted its position in Guardant Health by 16.1% during the third quarter. TD Asset Management Inc now owns 188,810 shares of the company's stock valued at $11,797,000 after acquiring an additional 26,210 shares during the last quarter. Algert Global LLC boosted its stake in Guardant Health by 169.1% in the third quarter. Algert Global LLC now owns 120,114 shares of the company's stock valued at $7,505,000 after acquiring an additional 75,474 shares in the last quarter. Finally, Iron Triangle Partners LP boosted its stake in Guardant Health by 33.3% in the third quarter. Iron Triangle Partners LP now owns 400,000 shares of the company's stock valued at $24,992,000 after acquiring an additional 100,000 shares in the last quarter. Institutional investors own 92.60% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on GH. BTIG Research set a $160.00 price target on Guardant Health and gave the stock a "buy" rating in a report on Wednesday, May 27th. Mizuho upped their price objective on Guardant Health from $135.00 to $175.00 and gave the company an "outperform" rating in a research report on Monday, June 8th. TD Cowen reiterated a "buy" rating on shares of Guardant Health in a research report on Thursday, May 21st. Barclays boosted their target price on shares of Guardant Health from $120.00 to $150.00 and gave the company an "overweight" rating in a research note on Wednesday, June 24th. Finally, The Goldman Sachs Group assumed coverage on shares of Guardant Health in a report on Friday, June 5th. They issued a "buy" rating and a $165.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $144.82.
View Our Latest Stock Report on Guardant Health
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
